OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Wednesday morning. The brokerage issued a sell rating on the stock.

Several other research firms also recently weighed in on OCX. Benchmark reiterated a speculative buy rating and issued a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. Stephens reiterated an equal weight rating and issued a $4.00 target price on shares of OncoCyte in a report on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Hold and a consensus target price of $4.06.

OncoCyte Price Performance

OCX stock opened at $2.46 on Wednesday. The firm’s 50 day moving average price is $2.92 and its 200-day moving average price is $3.04. OncoCyte has a one year low of $2.08 and a one year high of $6.20.

Insiders Place Their Bets

In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 2,420,000 shares of the company’s stock in a transaction on Thursday, April 11th. The stock was acquired at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The purchase was disclosed in a filing with the SEC, which is available through this link. In other news, Director Andrew Arno acquired 33,898 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was acquired at an average cost of $2.95 per share, with a total value of $99,999.10. Following the transaction, the director now owns 69,054 shares in the company, valued at $203,709.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The shares were purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the transaction, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. Insiders acquired a total of 2,457,288 shares of company stock worth $7,176,400 over the last 90 days. Corporate insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.